Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1.

Caroline Robert Celeste Lebbè Thierry Lesimple Eija Lundström Valérie Nicolas Bruno Gavillet Philippa Crompton Baryour Baroudijian Émilie Routier Ferdy J Lejeune

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

This combination was well tolerated. Disease control was obtained in 42.8% (RECIST) and 50% (iRECIST). The evidence for thymus rejuvenation was limited.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
stem cells